跳至主要内容
临床试验/NL-OMON50838
NL-OMON50838招募中4 期

Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease. - GENPAD

Academisch Medisch Centrum0 个研究点目标入组 2,276 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
2,276

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - age > 16 years
  • - obtained written informed consent
  • - indication for monotherapy clopidogrel 75mg once daily
  • - ankle-brachial index < 0.9 and/or toe brachial index < 0.5
  • - current or previous symptoms due to insufficient vascularization of one or
  • two lower extremities, including intermittent claudication, pain at rest and/or
  • gangrene (Rutherford category 1-6)
  • - consulting a vascular surgeon for diagnosis, treatment and/or follow-up of
  • PAD symptoms

排除标准

  • - known CYP2C19*2 and *3 status
  • - treated with coumarins, Non-vitamin K Oral Anti-Coagulants, unfractionated
  • heparin, low molecular weight heparins or double antiplatelet therapy for other
  • indications
  • - contraindication for clopidogrel, acetylsalicylic acid and/or rivaroxaban
  • - life expectancy of less than 1 year
  • - pregnant or breastfeeding women
  • - unable to give informed consent

研究者

相似试验